Skip to content

The Archways Program

Archways logo

Support for Patients Starting Orenitram

Managing PAH and starting Orenitram may leave patients with questions. That’s why enrolling in the United Therapeutics Archways program may provide your patients with numerous helpful resources, including a Virtual Patient Educator, available at no cost once they’ve been prescribed Orenitram.

A United Therapeutics Virtual Patient Educator will connect with your patient one-on-one and answer questions about:

  • Disease information
  • Starting Orenitram
  • Understanding their dosing schedule
  • What to expect when starting the Specialty Pharmacy process

3 Ways to Get Started

Visit www.UTArchways.com

Call the Archways program

at 1-888-327-2492

Text “START” to 882724

(Standard data rates may apply)

United Therapeutics and the Archways program do not provide medical advice. Patients are
advised to consult with their HCP with any specific questions or concerns about their treatment.

Additional Support Resources

Cost and Financial Support

See how United Therapeutics may help with cost assistance and support for patients taking Orenitram.

Specialty Pharmacy Support

Read about how Specialty Pharmacies may help your patients access Orenitram, schedule nurse visits, and much more.

Video and Resource Library

To access helpful videos, downloadable resources for patients, and recent publications, visit Video and Resource Library.

PAH=pulmonary arterial hypertension.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

INDICATION

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).